NEJM· Dana V. Rizk Jonathan Barratt Yusuke Suzuki Hong Zhang Muh Geot Wong Adrian Liew Richard Lafayette Vladimír Tesař Hernán Trimarchi Kevin Carroll Ian S.D. Roberts Vivekanand Jha Alejandra Quevedo Seung Hyeok Han Rosnawati Yahya Chee Kay Cheung Raja Ramachandran Michael Walsh Bobby Chacko Manuel Praga Jin-Bor Chen José Suassuna Jing Xia Lokesh Shah and Vlado Perkovicthe VISIONARY Trial Investigators Group*·· 1 day agoPickScore67
Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis
In brief
The NEJM has published online ahead of print the final analysis of the phase 3 VISIONARY trial, reporting efficacy and safety results of sibeprenlimab in IgA nephropathy.
Why it matters
As the final phase 3 analysis of sibeprenlimab in IgA nephropathy, it provides definitive data on the efficacy and safety of this anti-APRIL monoclonal antibody.
Source: NEJM · nejm.org